Hepatitis B virus kinetics and mathematical modeling.
In this article, we review modeling and interpretation of kinetics data obtained from patients with chronic hepatitis B virus infection that has been treated with lamivudine, adefovir dipivoxil, and lamivudine plus famciclovir combination therapy.
Perelson
Alan S
AS
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA. asp@lanl.gov
Ribeiro
Ruy M
RM
D000225:Adenine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood / Q000187:drug effects* / Q000235:genetics; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D022781:Hepatocytes / Q000187:drug effects / Q000821:virology; D019259:Lamivudine / Q000493:pharmacokinetics / Q000627:therapeutic use; D008954:Models, Biological; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D019562:Viral Load; D014771:Virion / Q000502:physiology
D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C053001:adefovir; D000225:Adenine; C106812:adefovir dipivoxil